Paul Mraz Appointed President and CEO of FzioMed

FzioMed Inc. has appointed industry veteran Paul Mraz as its new president/CEO and board member. He replaces with John Krelle, who retired after a 17-year tenure.
 
“On behalf of the Board of Directors, I want to thank John for his many years of service to FzioMed, his outstanding leadership, commitment to our values and dedication to the company, its employees, customers and stakeholders. John led FzioMed through a period of growth and transformation and we wish him the very best in his retirement,” Executive Board Chairman Ron Haynes said.
 
Mraz joins the company with broad industry experience, having served as president and CEO at multiple medical device and biomaterials companies. From innovative startups to the world’s largest healthcare companies, Mraz has been responsible for the success of numerous medical technologies during his more than 30-year career in the life sciences industry. Most recently, he was president and CEO of ApiFix Ltd., acquired by OrthoPediatrics Corp. in 2020, where he continued to serve as senior vice president and general manager of its Scoliosis franchise.

“We are very pleased to name Paul Mraz as president and CEO of FzioMed. Paul is a seasoned leader with a successful track record of execution and shareholder value creation across numerous medical device businesses worldwide. He brings an incredible amount of energy and strategic skills to the company as well as a deep understanding of global surgical markets,” Haynes said.
 
“The FzioMed team has built a strong organization with a bright future, and I am honored to lead the next phase of the company’s growth,” Mraz said in his first formal statement as president/CEO. “Our flagship family of Oxiplex products have 20 years of clinical use with more than 750,000 units utilized in 72 countries around the globe. I am excited to join FzioMed at a time when we look to broaden the adoption of our Oxiplex technology across orthopedics, spine and women’s health including our first commercial introduction in the United States.”
 
Founded in 1996, FzioMed is a privately held medical device and biomaterials company focused exclusively on spine/orthopedic, peritoneal, and gynecological surgical technology. The company develops, manufactures absorbable adhesion barriers based on its patented polymer technology and currently markets and distributes its products under various brand names including Oxiplex, Oxiplex/SP, Oxiplex/AP, Oxiplex/IU, Dynavisc, MediShield, and Interpose. Oxiplex is an absorbable gel applied to tissues and organs following surgery and related procedures. In spine surgery, Oxiplex creates a temporary physical barrier between adjacent tissues and has been shown in multiple peer reviewed studies to reduce leg pain, back pain and neurologic symptoms.
 
FzioMed, Oxiplex, Oxiplex/SP, Oxiplex/AP, Oxiplex/IU, Dynavisc, and Interpose are registered trademarks of FzioMed Inc.